Fatty liver disease is a growing health concern in the UK, particularly as the population ages. Many older adults wonder whether developing fatty liver is an inevitable part of getting older. Whilst non-alcoholic fatty liver disease (NAFLD) does become more common with advancing age, affecting approximately 25–30% of UK adults, most older people do not develop the condition. Understanding your individual risk factors—such as type 2 diabetes, obesity, and metabolic syndrome—is far more important than age alone in determining your likelihood of fatty liver disease.

How Common Is Fatty Liver in Older Adults?

Fatty liver disease, medically termed hepatic steatosis, is increasingly prevalent in older populations, though it does not affect the majority of elderly individuals. Current epidemiological data suggests that non-alcoholic fatty liver disease (NAFLD) affects approximately 25–30% of the general adult population in the UK, with prevalence rising notably in those over 60 years of age. However, this means that most older people do not develop fatty liver disease, even though age is recognised as a significant risk factor. (You may also encounter the newer term metabolic dysfunction-associated steatotic liver disease [MASLD], though NICE and NHS guidance currently use NAFLD.)

The prevalence varies considerably depending on associated metabolic conditions. Among older adults with type 2 diabetes, obesity, or metabolic syndrome, rates may reach up to 60–70%, whereas those maintaining healthy weight and metabolic profiles have substantially lower risk. Population studies indicate that fatty liver becomes more detectable with advancing age, partly due to cumulative metabolic changes and partly because older adults undergo more frequent health screening and imaging investigations that incidentally detect hepatic steatosis.

It is important to distinguish between simple hepatic steatosis (fat accumulation without significant inflammation) and non-alcoholic steatohepatitis (NASH), which involves inflammation and potential progression to fibrosis. Whilst fatty infiltration of the liver is relatively common in older age groups, progression to advanced liver disease remains less frequent. The NHS and NICE recognise NAFLD as a growing public health concern, particularly given the ageing population and rising rates of obesity and diabetes. Understanding individual risk factors is more clinically relevant than age alone when assessing likelihood of developing fatty liver disease in later life.

Sources: NICE NG49 (Non-alcoholic fatty liver disease: assessment and management); NHS NAFLD webpage; British Liver Trust NAFLD resources.

Why Does Fatty Liver Develop with Age?

The development of fatty liver disease in older adults results from a complex interplay of metabolic, physiological, and lifestyle factors that accumulate over decades. Age-related changes in body composition play a central role: older adults typically experience increased visceral adiposity and reduced muscle mass (sarcopenia), even when overall body weight remains stable. This shift in body composition promotes insulin resistance, a key driver of hepatic fat accumulation.

Insulin resistance impairs the liver's ability to regulate glucose and lipid metabolism effectively. When peripheral tissues become less responsive to insulin, the liver compensates by increasing de novo lipogenesis (fat synthesis) whilst simultaneously reducing fat oxidation. This metabolic imbalance leads to triglyceride accumulation within hepatocytes. Additionally, age-related decline in mitochondrial function reduces the liver's capacity to metabolise fatty acids efficiently, further contributing to steatosis.

Other physiological changes associated with ageing include:

• Reduced physical activity levels, leading to decreased energy expenditure and metabolic rate

• Hormonal changes, particularly declining growth hormone and sex hormones, which affect fat distribution and metabolism

• Chronic low-grade inflammation (inflammaging), which exacerbates metabolic dysfunction

• Polypharmacy, as certain medications commonly prescribed to older adults—such as corticosteroids, tamoxifen, amiodarone, valproate, and methotrexate—may contribute to hepatic steatosis. Your clinician will review all your medications for potential liver effects.

Lifestyle factors accumulated over a lifetime, including dietary patterns high in refined carbohydrates and saturated fats, also contribute significantly. Current understanding emphasises that fatty liver develops when several factors converge—genetic predisposition, metabolic dysfunction, lipotoxicity, oxidative damage, and gut microbiome alterations—all of which become more pronounced with advancing age. Understanding these mechanisms helps clinicians target modifiable risk factors in older patients.

Sources: NICE NG49 NAFLD: assessment and management (risk factors); EASL–EASD–EASO clinical practice guideline on MASLD.

Recognising Fatty Liver Disease in Elderly Patients

Fatty liver disease typically presents asymptomatically in its early stages, making recognition challenging, particularly in older adults who may attribute vague symptoms to normal ageing. Most cases are detected incidentally during abdominal ultrasound examinations performed for unrelated reasons, or when routine blood tests reveal elevated liver enzymes, specifically alanine aminotransferase (ALT) and aspartate aminotransferase (AST). It is important to note that liver function tests (LFTs) can be entirely normal in NAFLD, including in people with advanced fibrosis, so normal results do not exclude the condition.

When symptoms do occur, they are often non-specific and may include:

• Persistent fatigue and malaise, which older patients may dismiss as age-related

• Right upper quadrant discomfort or a sensation of fullness, though frank pain is uncommon

• Unexplained weight changes or difficulty managing blood glucose levels in diabetic patients

Clinical examination may reveal hepatomegaly (enlarged liver), though this finding is neither sensitive nor specific. In more advanced cases progressing to cirrhosis, signs such as jaundice, ascites, peripheral oedema, or spider naevi may develop, but these represent late-stage disease.

Diagnostic investigation typically follows NICE guidance and includes:

• Liver function tests (LFTs) and metabolic screening (lipid profile, HbA1c, fasting glucose)

• Abdominal ultrasound as the first-line imaging modality to assess hepatic echogenicity, though a normal scan does not rule out NAFLD, particularly in mild steatosis or obesity

• Non-invasive fibrosis risk stratification using the FIB-4 index or NAFLD Fibrosis Score as the first step. In older adults (≥65 years), age-adjusted cut-offs are used to improve accuracy. If these scores suggest possible advanced fibrosis, NICE recommends the Enhanced Liver Fibrosis (ELF) blood test as the second-line assessment. Transient elastography (FibroScan®) may be used as an adjunct where available.

In older patients, it is crucial to exclude alternative causes of liver disease, including alcohol-related liver disease (through careful history-taking), viral hepatitis (hepatitis B and C serology), autoimmune hepatitis, haemochromatosis, and medication-induced hepatotoxicity. Depending on clinical context, testing for thyroid disease and coeliac disease may also be appropriate. The presence of metabolic risk factors—obesity, type 2 diabetes, hypertension, and dyslipidaemia—strongly supports a diagnosis of NAFLD.

Sources: NICE NG49 NAFLD: assessment and management; BSG guideline on investigation of abnormal liver blood tests.

Managing and Preventing Fatty Liver in Later Life

Management of fatty liver disease in older adults centres on lifestyle modification and optimisation of metabolic health, with the primary goal of preventing progression to NASH, fibrosis, and cirrhosis. NICE guidance emphasises a holistic approach addressing all components of metabolic syndrome.

Weight management remains the cornerstone of treatment. Evidence demonstrates that achieving ≥7–10% total body weight loss can lead to NASH resolution, and ≥10% weight loss may improve liver fibrosis. For older adults, weight loss strategies must be carefully tailored to preserve muscle mass and functional capacity. A gradual, supervised approach combining modest caloric restriction with resistance training is recommended, rather than aggressive dieting which may exacerbate sarcopenia. Referral to NHS weight management services or, where criteria are met, specialist bariatric services should be considered.

Dietary modifications should focus on:

• Adopting a Mediterranean-style diet rich in vegetables, fruits, whole grains, legumes, nuts, and olive oil

• Reducing intake of refined carbohydrates, added sugars (particularly fructose), and saturated fats

• Limiting processed foods and sugar-sweetened beverages

• Moderating portion sizes whilst ensuring adequate protein intake to maintain muscle mass

• Following UK Chief Medical Officers' alcohol guidance: no more than 14 units per week, spread over 3 or more days, with several alcohol-free days each week

Physical activity is equally important. UK Chief Medical Officers recommend at least 150 minutes of moderate-intensity aerobic activity weekly, supplemented with resistance or strength training on two or more days to combat sarcopenia. For older adults with mobility limitations, adapted exercises and physiotherapy referral may be appropriate.

Pharmacological management focuses on treating associated metabolic conditions. Optimal control of type 2 diabetes, hypertension, and dyslipidaemia is essential. Statins are safe and indicated when clinically appropriate in people with NAFLD and should not be withheld due to concerns about liver disease. Certain diabetes medications—particularly pioglitazone, vitamin E (in selected non-diabetic adults with biopsy-proven NASH), and GLP-1 receptor agonists (such as liraglutide)—have shown benefits in reducing hepatic steatosis in clinical trials. However, none of these are licensed in the UK for the treatment of NAFLD or NASH and should only be used under specialist hepatology or endocrinology supervision. Important safety considerations include:

• Pioglitazone: contraindicated in heart failure; associated with fluid retention, fracture risk, and a potential bladder cancer signal (MHRA Drug Safety Update). Requires careful patient selection and monitoring.

• Vitamin E: long-term safety data are limited; use restricted to specialist-led cases with biopsy-confirmed NASH.

• GLP-1 receptor agonists: not licensed for NAFLD/NASH; use is off-label and requires specialist initiation.

Regular monitoring is essential. NICE recommends repeating non-invasive fibrosis assessment (FIB-4/NFS and, if indicated, ELF) approximately every 2–3 years in people without advanced fibrosis, with more frequent reassessment if disease progresses. Older patients should be counselled to avoid hepatotoxic substances and unnecessary medications. All medications should be reviewed regularly for potential liver effects.

Patients and healthcare professionals are encouraged to report suspected adverse drug reactions via the MHRA Yellow Card Scheme (https://yellowcard.mhra.gov.uk or search 'Yellow Card' online).

Sources: NICE NG49 NAFLD: assessment and management; MHRA Drug Safety Update on pioglitazone; EMC Summaries of Product Characteristics (SmPCs) for pioglitazone and liraglutide; UK Chief Medical Officers' alcohol and physical activity guidelines.

When to Seek Medical Advice About Fatty Liver

Older adults should consult their GP if they experience persistent or unexplained symptoms that may indicate liver dysfunction, even though fatty liver disease is often asymptomatic in early stages. Key symptoms warranting medical review include ongoing fatigue that impacts daily activities, unexplained weight loss or gain, persistent abdominal discomfort in the right upper quadrant, or new-onset difficulty managing previously stable diabetes.

Urgent medical attention is required if signs of advanced liver disease develop. Call 999 or attend A&E immediately if you experience:

• Jaundice (yellowing of skin or eyes)

• Dark urine or pale stools

• Vomiting blood or passing black, tarry stools

• Confusion or altered mental state, particularly if accompanied by jaundice (hepatic encephalopathy)

• Severe abdominal swelling (ascites) or sudden worsening of leg swelling

• Easy bruising or bleeding, which may indicate impaired liver synthetic function

Patients with known risk factors for fatty liver disease—particularly those with type 2 diabetes, obesity (BMI >30 kg/m²), metabolic syndrome, or elevated liver enzymes—should request assessment even in the absence of symptoms. There is no UK population screening programme for NAFLD, but proactive case-finding in at-risk groups through primary care is appropriate and allows early intervention before significant liver damage occurs.

If fatty liver disease has been diagnosed, patients should maintain regular follow-up appointments as recommended by their healthcare team. The frequency of monitoring depends on disease severity and presence of fibrosis, typically involving repeat non-invasive fibrosis assessment every 2–3 years if no advanced fibrosis is present. Those with advanced fibrosis or cirrhosis require specialist hepatology input and six-monthly ultrasound surveillance for hepatocellular carcinoma (HCC). Variceal screening is performed via endoscopy according to hepatology guidance and Baveno criteria, with intervals determined by findings rather than a fixed six-monthly schedule.

Older adults should inform their GP about all medications and supplements they take, as some may contribute to or exacerbate liver disease. Any new prescriptions should be reviewed for potential hepatotoxicity. Additionally, patients planning significant dietary changes or weight loss programmes should discuss these with their healthcare provider to ensure approaches are safe and appropriate for their age and comorbidities. Early engagement with healthcare services optimises outcomes and prevents progression to irreversible liver damage.

Sources: NHS NAFLD webpage; NICE NG49 NAFLD: assessment and management; BSG/BASL guidance on variceal screening and surveillance; NICE guidance on cirrhosis assessment and HCC surveillance.

Frequently Asked Questions